1-20 of 72 results for house:"House of Lords"
Librarians' tools
- Search time
- 0.421 seconds
- Solr query time
- 0.008 seconds
- Search query
- house:"House of Lords"
- We searched for
- legislature_ses:25277
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask Her Majesty's Government what facts would influence whether a charge of assault would be brought against a person working in a healthcare environment who knowingly was carrying COVID-19, with or without intention to transmit the virus to another person.
To ask Her Majesty's Government what facts would influence whether a charge of assault would be brought against a person working in a healthcare environment who knowingly was carrying COVID-19, with or without intention to transmit the virus to another person.
National Health Service organisations should consider the specific facts in a case-by-case basis and in accordance with their local disciplinary policy and procedures. Any investigation should establish whether the staff member intentionally, recklessly, carelessly, or negligently put patients and/or other members of staff at risk of infection. This may result in dismissal as the ultimate sanction.
If any internal investigation identifies a criminal offence has been committed, the employing organisation will need to make a referral to the relevant police force. Any charges of assault would be a matter for the police and Civil Court.
My Lords, would the Minister confirm that deliberately misleading Parliament and the House of Commons is contempt under the rules of Parliament? If it is shown that the Prime Minister deliberately misled Parliament on what he knew, he would be in contempt of the House of Commons, and he would...
My Lords, would the Minister confirm that deliberately misleading Parliament and the House of Commons is contempt under the rules of Parliament? If it is shown that the Prime Minister deliberately misled Parliament on what he knew, he would be in contempt of the House of Commons, and he would...
My Lords, if, after Friday, without the knowledge of management as to vaccination, an unvaccinated person working in a care home knowingly or unknowingly transmits the virus to a care home resident, does not the act of transmission constitute a criminal act under a legal definition of assault? Would not...
My Lords, if, after Friday, without the knowledge of management as to vaccination, an unvaccinated person working in a care home knowingly or unknowingly transmits the virus to a care home resident, does not the act of transmission constitute a criminal act under a legal definition of assault? Would not...
Is not the answer to the question asked by my noble friend that the Prime Minister was acting irresponsibly and was wrong?
Is not the answer to the question asked by my noble friend that the Prime Minister was acting irresponsibly and was wrong?
My Lords, I greatly welcome this debate and the tabling by my noble friend of her very relevant amendment. According to the Explanatory Note, the regulations provide that for,
“the purposes of preventing, detecting and controlling the spread of infection, registered persons … must secure that a person … does not...
My Lords, I greatly welcome this debate and the tabling by my noble friend of her very relevant amendment. According to the Explanatory Note, the regulations provide that for,
“the purposes of preventing, detecting and controlling the spread of infection, registered persons … must secure that a person … does not...
My Lords, following calls from the BMA, the RCM and Cambridge University Hospitals, can we have an assurance that in every setting where health workers are caring for patients with suspected or confirmed coronavirus, the health worker will be wearing at least a close-fitting FFP3 mask, thereby maximising personal protection?...
My Lords, following calls from the BMA, the RCM and Cambridge University Hospitals, can we have an assurance that in every setting where health workers are caring for patients with suspected or confirmed coronavirus, the health worker will be wearing at least a close-fitting FFP3 mask, thereby maximising personal protection?...
My Lords, is it not obvious that if you reduce mask wearing on public transport and in public places, those who believe they are more exposed to the virus will then reduce their use of public transport and avoid public places? People who are fearful of more liberated environments will...
My Lords, is it not obvious that if you reduce mask wearing on public transport and in public places, those who believe they are more exposed to the virus will then reduce their use of public transport and avoid public places? People who are fearful of more liberated environments will...
My Lords, yesterday, in a perhaps intemperate intervention, I expressed frustration over the Government’s vaccine manufacturing strategy. However, the Minister’s response—characteristically frank and generous—left me both alarmed and even more concerned. The noble Lord, Lord Bethell, said that
“we make hardly any vaccine at all. It is not for us as...
My Lords, yesterday, in a perhaps intemperate intervention, I expressed frustration over the Government’s vaccine manufacturing strategy. However, the Minister’s response—characteristically frank and generous—left me both alarmed and even more concerned. The noble Lord, Lord Bethell, said that
“we make hardly any vaccine at all. It is not for us as...
My Lords, following the comments of the noble Baroness, Lady Sugg, when Gordon Brown called the G7 summit an “unforgivable moral failure”, was he not right? With potentially billions to vaccinate, the West has miserably abandoned the moral high ground on vaccine supply, leaving it to the Chinese and Russians...
My Lords, following the comments of the noble Baroness, Lady Sugg, when Gordon Brown called the G7 summit an “unforgivable moral failure”, was he not right? With potentially billions to vaccinate, the West has miserably abandoned the moral high ground on vaccine supply, leaving it to the Chinese and Russians...
Do Ministers accept that more patient choice would help in dealing with problems over spread due to vaccine hesitancy? Having in mind data on vaccine hesitancy in the case of the AstraZeneca vaccine, when will we have a decision on the authorisation of vaccines of a different brand to deal with vaccine brand hesitancy?
Do Ministers accept that more patient choice would help in dealing with problems over spread due to vaccine hesitancy? Having in mind data on vaccine hesitancy in the case of the AstraZeneca vaccine, when will we have a decision on the authorisation of vaccines of a different brand to deal with vaccine brand hesitancy?
That has not been the feedback from the public in the round. There are significant issues around the supply of vaccine, and we very much take an approach of getting the vaccine out of the warehouse and into the arms of the public in as speedy a manner as we possibly can. We are not aware of a huge amount of brand prejudice among the public, and that is entirely right, because all the vaccines are effective: that is the view of the MHRA, the JCVI and the British public.
On the issue of Covid vaccination policy for rough sleepers, is it not true that they are not treated nationally as a priority group for vaccination and that we have a postcode lottery in operation? Some areas treat them as a priority, others do not, yet they are a particularly...
On the issue of Covid vaccination policy for rough sleepers, is it not true that they are not treated nationally as a priority group for vaccination and that we have a postcode lottery in operation? Some areas treat them as a priority, others do not, yet they are a particularly...
To ask Her Majesty's Government what (1) estimate they made, and (2) audit they undertook, of the potential (a) demand, and (b) availability, of sub-60 degree freezer capacity in the UK prior to the Pfizer COVID-19 vaccine rollout in 2020.
To ask Her Majesty's Government what (1) estimate they made, and (2) audit they undertook, of the potential (a) demand, and (b) availability, of sub-60 degree freezer capacity in the UK prior to the Pfizer COVID-19 vaccine rollout in 2020.
Public Health England (PHE) is responsible for the central storage and distribution of ultra-low temperature COVID-19 vaccines. In its preparations to receive vaccines, PHE determined the freezer capacity requirement to support the United Kingdom programme during summer 2020 and secured the freezers against that requirement. These were commissioned and in service before arrival of the vaccine. They provide sufficient storage for approximately five million doses of COVID-19 vaccines which require minus 60 degree Celsius storage or below.
Her Majesty's Government whether they have had any discussions with the World Health Organization (WHO) about when the governments of (1) Italy, and (2) France, first reported the emergence of COVID-19 to WHO; if so, when in (a) 2019, and (b) 2020, any such emergence was reported by those countries; what...
Her Majesty's Government whether they have had any discussions with the World Health Organization (WHO) about when the governments of (1) Italy, and (2) France, first reported the emergence of COVID-19 to WHO; if so, when in (a) 2019, and (b) 2020, any such emergence was reported by those countries; what...
The United Kingdom has not had any specific discussions with the World Health Organization on the emergence of COVID-19 in France and Italy. The UK Government received notification of France and Italy’s first COVID-19 cases through the European Early Warning and Response System. France reported its first three COVID-19 cases on 24 January 2020. Italy reported its first two COVID-19 cases on 31 January 2020.
The Government has not made any assessment of reports of COVID-19 appearing in wastewater in Barcelona in 2019. In the UK, a national wastewater surveillance programme was announced on 12 June 2020 by the Department of Environment, Food and Rural Affairs, the Scottish and Welsh devolved administrations, focusing on sewage monitoring as part of an advance warning system to detect new outbreaks of COVID-19.
To ask Her Majesty's Government what (1) discussions they have had, or (2) approaches were made to, or by, Warren Medical Limited about the provision of services and supplies related to COVID-19.
To ask Her Majesty's Government what (1) discussions they have had, or (2) approaches were made to, or by, Warren Medical Limited about the provision of services and supplies related to COVID-19.
The Department has not had any discussions or approaches from Warren Medical Limited about the provision of services and supplies related to COVID-19.
Her Majesty's Government whether there is any evidence of variants of COVID-19 which can be traced to specific countries of origin; and if so, what proportion of reported COVID-19 cases have been linked to the variant of COVID-19 from Italy.
Her Majesty's Government whether there is any evidence of variants of COVID-19 which can be traced to specific countries of origin; and if so, what proportion of reported COVID-19 cases have been linked to the variant of COVID-19 from Italy.
It is common for viruses to mutate - over 4,000 variants of SARS-CoV-2 have been identified worldwide. The United Kingdom has a world leading surveillance system that supports the detection, analysis and identification of any variants circulating globally which may be of concern.
COVID-19 Genomics UK will continue to lead on monitoring virus samples for new variants. The Department and Public Health England will continue to study the virus closely to understand how it is behaving, where it might have originated from and the spread of the new variant across the UK.
My Lords, we are told that by February we are to return to tiered arrangements geared to a national vaccine rollout programme, yet we also learned of discussions over a new tier 5, which could introduce even tougher rules.
Before decisions are taken on tier 5 restrictions, I make a plea:...
My Lords, we are told that by February we are to return to tiered arrangements geared to a national vaccine rollout programme, yet we also learned of discussions over a new tier 5, which could introduce even tougher rules.
Before decisions are taken on tier 5 restrictions, I make a plea:...
To ask Her Majesty's Government whether the COVID-19 planned for use vaccines prevent those vaccinated from transmitting the disease.
To ask Her Majesty's Government whether the COVID-19 planned for use vaccines prevent those vaccinated from transmitting the disease.
To date the Medicines and Healthcare products Regulatory Agency (MHRA), as well as independent expert advisors on the Commission on Human Medicines and its Expert Working Groups, have completed the assessment of the quality, safety and efficacy data only for the Pfizer/BioNTech vaccine. This vaccine is an mRNA vaccine and data supported a two dose regimen. Efficacy was evaluated in terms of prevention of COVID-19 caused by the SARS-CoV-2 virus, in terms of vulnerability to COVID-19 of the person vaccinated. Clinical trial data showed that, compared to the placebo, efficacy of the Pfizer/BioNTech vaccine from first COVID-19 occurrence from seven days after dose two in participants with or without evidence of prior infection with SARS-CoV-2 was 94.6% - a 95% credible interval of 89.9% to 97.3%).
There is currently no data available regarding transmission of COVID-19 to others in a person who has been vaccinated using any of the COVID-19 vaccines. There is also currently no data available for any COVID-19 vaccine on the period after vaccination for which a person can remain asymptomatic.
To ask Her Majesty's Government to what extent a person who receives only one dose of (1) an adenovirus vector, or (2) an mRNA, COVID-19 vaccination is (a) vulnerable to COVID-19 themselves, and (b) able to transmit the disease on to a second person.
To ask Her Majesty's Government to what extent a person who receives only one dose of (1) an adenovirus vector, or (2) an mRNA, COVID-19 vaccination is (a) vulnerable to COVID-19 themselves, and (b) able to transmit the disease on to a second person.
To date the Medicines and Healthcare products Regulatory Agency (MHRA), as well as independent expert advisors on the Commission on Human Medicines and its Expert Working Groups, have completed the assessment of the quality, safety and efficacy data only for the Pfizer/BioNTech vaccine. This vaccine is an mRNA vaccine and data supported a two dose regimen. Efficacy was evaluated in terms of prevention of COVID-19 caused by the SARS-CoV-2 virus, in terms of vulnerability to COVID-19 of the person vaccinated. Clinical trial data showed that, compared to the placebo, efficacy of the Pfizer/BioNTech vaccine from first COVID-19 occurrence from seven days after dose two in participants with or without evidence of prior infection with SARS-CoV-2 was 94.6% - a 95% credible interval of 89.9% to 97.3%).
There is currently no data available regarding transmission of COVID-19 to others in a person who has been vaccinated using any of the COVID-19 vaccines. There is also currently no data available for any COVID-19 vaccine on the period after vaccination for which a person can remain asymptomatic.
To ask Her Majesty's Government to what extent a person who completes a two-dose course of (1) an adenovirus vector, and (2) an mRNA, COVID-19 vaccination remains (a) vulnerable to COVID-19 themselves, and (b) able to transmit the disease on to a second person.
To ask Her Majesty's Government to what extent a person who completes a two-dose course of (1) an adenovirus vector, and (2) an mRNA, COVID-19 vaccination remains (a) vulnerable to COVID-19 themselves, and (b) able to transmit the disease on to a second person.
To date the Medicines and Healthcare products Regulatory Agency (MHRA), as well as independent expert advisors on the Commission on Human Medicines and its Expert Working Groups, have completed the assessment of the quality, safety and efficacy data only for the Pfizer/BioNTech vaccine. This vaccine is an mRNA vaccine and data supported a two dose regimen. Efficacy was evaluated in terms of prevention of COVID-19 caused by the SARS-CoV-2 virus, in terms of vulnerability to COVID-19 of the person vaccinated. Clinical trial data showed that, compared to the placebo, efficacy of the Pfizer/BioNTech vaccine from first COVID-19 occurrence from seven days after dose two in participants with or without evidence of prior infection with SARS-CoV-2 was 94.6% - a 95% credible interval of 89.9% to 97.3%).
There is currently no data available regarding transmission of COVID-19 to others in a person who has been vaccinated using any of the COVID-19 vaccines. There is also currently no data available for any COVID-19 vaccine on the period after vaccination for which a person can remain asymptomatic.
To ask Her Majesty's Government for how long a person who has received the two-doses of the COVID-19 vaccine required under the vaccination protocols is able to transmit COVID-19 on to a second person
To ask Her Majesty's Government for how long a person who has received the two-doses of the COVID-19 vaccine required under the vaccination protocols is able to transmit COVID-19 on to a second person
To date the Medicines and Healthcare products Regulatory Agency (MHRA), as well as independent expert advisors on the Commission on Human Medicines and its Expert Working Groups, have completed the assessment of the quality, safety and efficacy data only for the Pfizer/BioNTech vaccine. This vaccine is an mRNA vaccine and data supported a two dose regimen. Efficacy was evaluated in terms of prevention of COVID-19 caused by the SARS-CoV-2 virus, in terms of vulnerability to COVID-19 of the person vaccinated. Clinical trial data showed that, compared to the placebo, efficacy of the Pfizer/BioNTech vaccine from first COVID-19 occurrence from seven days after dose two in participants with or without evidence of prior infection with SARS-CoV-2 was 94.6% - a 95% credible interval of 89.9% to 97.3%).
There is currently no data available regarding transmission of COVID-19 to others in a person who has been vaccinated using any of the COVID-19 vaccines. There is also currently no data available for any COVID-19 vaccine on the period after vaccination for which a person can remain asymptomatic.